On February 10, 2025, Namixin (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as "Namixin") announced the completion of its Series A financing. This financing is jointly invested by Chengdu Bio City Guosheng Capital and Enran Venture Capital. The financing funds will mainly be used to promote clinical research of the NR222 project and the development of new projects.

The implementation of this round of financing is a recognition of Namixin by the investors and injects strong impetus into the company's promotion of subsequent clinical research.

Namixin was founded in 2021 and registered in Lingang, Shanghai. It is a biotechnology enterprise specializing in the research and development of new vaccines/drugs in the mRNA field. The founding team of the company has a profound research background in the mRNA field and has held important positions in top pharmaceutical research institutions and pharmaceutical companies both domestically and internationally, effectively mastering the core know-how of the mRNA field.

picture

Dr. Qian Zhikang, the founder of the company, worked as a researcher at Washington University in St. Louis, specializing in the field of virology research. After returning to China, Dr. Qian Zhikang served as the leader of the herpes virus research team at the Chinese Academy of Sciences Shanghai Institute of Immunology and Infection (formerly the Chinese Academy of Sciences Shanghai Pasteur Institute), and made many pioneering research achievements in the field of herpes virus and modular protein nano vaccine. In 2021, he jointly participated in the establishment of Namixin Biotechnology, building a leading and complete mRNA vaccine/drug research and development and process platform covering target screening, antigen design, mRNA sequence design and optimization, prescription screening, pharmacological efficacy evaluation, etc.

In 2023, Dr. Liu Jun, who had previously served as the head of CMC at several leading international biopharmaceutical companies, joined Namixin. The addition of Dr. Liu Jun has further improved the company's research and industrialization capabilities, enhanced Namixin's advantages on the CMC platform, and promoted product process development, sample production, quality, and registration work.

The non coding region sequence and codon optimization algorithm, AI/DeepLearning based antigen design and optimization, CircRNA purification process, and LNP freeze-drying process independently developed by Namixin have overcome industry difficulties and pain points.

At present, the freeze-dried mRNA respiratory syncytial virus (RSV) vaccine independently developed by the company has obtained implied permission for clinical trials from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (acceptance number: CXSL2400681）， It is the first freeze-dried mRNA vaccine variety in China to enter the clinical stage. This product has better immunogenicity and animal toxicity protection compared to overseas listed varieties, and has good safety. The product can be stored and transported stably for a long time at 2-8 ℃, enhancing the durability and effectiveness of vaccines and improving vaccine accessibility in low - and middle-income countries.

The company is also actively conducting research and development of other indications, and in the future, more products will enter clinical research, benefiting patients and becoming a leading vaccine drug research and development enterprise in the industry.

Mr. Deng Ming, CEO of Namixin Biotechnology, said, "Faced with the uncertainty of the macroeconomic environment and fluctuations in the capital market, biopharmaceutical financing is difficult, and the path of innovation and entrepreneurship is full of challenges. We are very grateful to Chengdu Bio City Guosheng Capital and Enran Venture Capital for recognizing and supporting Namixin Biotechnology. Namixin focuses on the mRNA field, adheres to source innovation, and has been established for more than three years. With less capital, we have solidly and rigorously promoted research and clinical work with good efficiency. The company will adhere to our beliefs and be committed to developing more valuable innovative products, preventing and treating diseases, improving life, and creating value for shareholders